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Breast cancer outcomes have markedly improved in
great part because of advances in therapy. These
improved outcomes, however, have been accompa-
nied by greater financial costs, toxicities, and over-
treatment of a substantial number of patients. Wemust
now focus on studies that leverage our accumulated
knowledge and use amore individualized approach for
the locoregional1 and systemic management of this
disease.2-4 De-escalation trials can be harder to per-
form as a result of the complexities of noninferiority
designs, difficulty in funding them, and human nature.
Behavioral economists find that people experience
negative feelings about losses more strongly than
positive feelings about gains of similar size.5 This
makes it harder to conduct trials that are designed to
treat breast cancer precisely rather than compre-
hensively, including studies that aim to de-escalate
standard therapy.
The need to better tailor therapy is especially relevant
in human epidermal growth factor receptor 2 (HER2)
–positive breast cancer. Before HER2 targeting, this
subtype had the poorest prognosis, but remarkable
improvements in disease-free and overall survival were
achieved with adjuvant trastuzumab6-8 and sub-
sequent reductions in the risk of recurrence were
observed with dual or sequential adjuvant anti-HER2
therapy.9,10 However, ensuring that new standards of
care are not simply statistically significant but clinically
meaningful has been challenging. For example, full
approval by the US Food and Drug Administration in
2017 of the addition of adjuvant pertuzumab to tras-
tuzumab plus chemotherapy was based on improved
3-year invasive disease-free survival (iDFS) from 93%
to 94% in the APHINITY trial,9 a statistically significant
but admittedly modest impact in the overall trial
population.
Trials that are designed to further tailor therapy in
HER2-positive disease will require tools for risk strat-
ification to evaluate de-escalation in patients who are
at lower risk for recurrence and to prioritize testing of
new therapies for those at higher risk. Using baseline
anatomic risk to select patients for therapy de-
escalation, the single-arm Adjuvant Trastuzumab
Paclitaxel (APT) trial demonstrated impressive
outcomes at 7 years with 93% disease-free survival
and 95% overall survival for stage I HER2-positive
disease.11 More recently, the KATHERINE trial iden-
tified patients who were at high risk of recurrence by
enrolling those with residual disease after neoadjuvant
trastuzumab—with pertuzumab in some patients—
plus combination chemotherapy. This trial demon-
strated that an escalation in adjuvant therapy using
the antibody–drug conjugate trastuzumab emtansine
(T-DM1) in such patients markedly improved 3-year
iDFS from 77% to 88%.12 These findings establish
residual disease after neoadjuvant therapy in HER2-
positive disease as a definable high risk group and as
a useful biomarker for clinical practice and clinical
research.13
Response to neoadjuvant therapy for HER2-positive
breast cancer is a valuable indicator by which to
characterize risk. The neoadjuvant approach is in-
creasingly the norm as it downstages local disease and
optimizes surgical management,14 and pathologic
complete response (pCR) is an accepted prognostic
marker.15 Given the value of pCR as an intermediate
prognostic marker for outcome, neoadjuvant therapy
has been endorsed as a research platform with which
to assess treatment effects in vivo and as a more ef-
ficient strategy to conduct smaller trials that target
specific breast cancer subtypes.16 This platform as-
sumes that shorter-term response will predict longer-
term survival, thereby accelerating the transition from
smaller neoadjuvant phase II trials to larger and de-
finitive adjuvant phase III randomized trials.17,18
The investment in this strategy was exemplified by the
2013 accelerated US Food and Drug Administration
approval of pertuzumab in the neoadjuvant setting
based in part on the NeoSphere trial in which the
addition of pertuzumab to trastuzumab plus docetaxel
substantially increased pCR from 29% to 46%.19
However, this and other neoadjuvant trials of dual
anti-HER2 therapy serve as a cautionary tale. Multiple
neoadjuvant phase II to III trials that examined either
lapatinib or pertuzumab added to trastuzumab plus
chemotherapy demonstrated a higher pCR with dual
therapy but were less predictive of meaningful out-
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the APHINITY trial that investigated the addition of per-
tuzumab to adjuvant trastuzumab met its statistical ob-
jective, whereas the ALTTO trial that tested the addition of
lapatinib to adjuvant trastuzumab did not,20 and in practice
the clinical improvement observed in both studies was
modest at best. Although this outcome might have been
predicted by more sophisticated modeling of the absolute
difference in pCR required to produce a meaningful im-
provement in recurrence for survival,18 the fact remains
that the use of pCR as a surrogate of survival to investigate
novel treatments with the hope of eliminating the need for
large adjuvant trials has thus far not been realized.
However, neoadjuvant trials have shown that a small but
meaningful subgroup of patients with HER2-positive dis-
ease can achieve a pCR with all-biologic regimens without
chemotherapy. In NeoSphere, 17% of patients who were
randomly assigned to just trastuzumab plus pertuzumab
achieved pCR, which was considerably lower than when
chemotherapy was included. Nevertheless, it is intriguing
that some patients seem to benefit from HER2-directed
therapy alone, a finding echoed in such trials as TBCRC
006, TBCRC 023, TBCRC 026, and PAMELA, in which
17% to 34% of patients assigned to trastuzumab with either
lapatinib or pertuzumab achieved pCR,21-24 with higher
rates observed in patients with estrogen receptor–negative
disease than estrogen receptor–positive disease. The
challenge now is to determine to what extent pCR itself is
associated with favorable outcomes regardless of the
treatment used to induce it.
In the article that accompanies this editorial, Hurvitz et al25
report on the secondary end points from the KRISTINE trial,
including 3-year measures of efficacy, safety, and patient-
reported outcomes. KRISTINE was a phase III trial that
randomly assigned patients with centrally confirmed HER2-
positive stage II to III operable breast cancer (tumor size
. 2 cm) to either six cycles of a regimen with limited che-
motherapy using T-DM1 plus pertuzumab (T-DM11P)
versus docetaxel, carboplatin, trastuzumab, and pertuzu-
mab (TCHP). Its primary objective was previously re-
ported26 and was largely viewed as a negative study for the
neoadjuvant T-DM11P combination as its pCR rate was
significantly lower compared with TCHP (44% v 56%).
Moreover, 7% of patients who received T-DM11P expe-
rienced disease progression during neoadjuvant therapy
compared with none on TCHP.
In the article by Hurvitz et al, KRISTINE investigators report
on the 3-year event-free survival (EFS; for all enrolled
patients) and iDFS (for those who went to surgery after six
cycles of study-assigned therapy). Patients who achieved
a pCR continued on the same HER2-targeted regimen after
surgery (T-DM11P or trastuzumab and pertuzumab [HP]).
Patients in the T-DM11P armwho had greater than 1 cm of
residual disease in the breast, involved lymph nodes, or
both were encouraged to undergo chemotherapy, and 24%
patients in the T-DM1 arm received postoperative
chemotherapy, including 33% (41 of 124) of those patients
with residual disease and 9% (nine of 99) of those
with pCR.
There are several important findings from this new report.
First, more patients experienced disease progression
during neoadjuvant T-DM11P (7%) than during TCHP
(0%), and the resulting lower 3-year EFS implies a worse
outcome when all patients are considered from study
start. Second, there were fewer grade 3 or higher adverse
events with T-DM11P during the neoadjuvant phase;
however, in the adjuvant setting, there was more toxicity
with T-DM11P, which is only partially explained by the
use of adjuvant chemotherapy and could represent
cumulative toxicity with T-DM1 that was also observed in
KATHERINE.12 Compared with HP, adjuvant T-DM11P
in the KRISTINE trial was associated with more grade 3 or
higher adverse events (24% v 9%) and events leading to
treatment discontinuation (18% v 4%).
The most intriguing finding, however, was that even though
EFS was numerically lower with T-DM11P compared with
TCHP (83% and 94%, respectively), iDFS—which by
definition excluded patients with progression during neo-
adjuvant therapy—was similar with the two regimens (93%
and 92%, respectively) but with wide confidence margins
(hazard ratio, 1.11; 95% CI, 0.52 to 2.40). In particular,
patients who achieved pCR with either regimen had ex-
cellent outcomes, with 3-year iDFS of approximately 97% in
each arm. Among the 223 patients who achieved pCR in
both arms, only five patients experienced disease re-
currence, including three in the T-DM11P arm (two CNS
and one distant non-CNS recurrence) and two patients in
the TCHP arm (both CNS). Although encouraging, these
survival data must be interpreted cautiously as they were
secondary descriptive objectives without associated hy-
pothesis testing.
The new results of the KRISTINE trial further reinforce the
notion that the neoadjuvant setting can serve as a plat-
form for risk stratification in clinical practice as well as for
the development of new treatments for HER2-positive
breast cancer. We already knew that pathologic response
is a patient-level prognostic marker for long-term out-
comes.15 Just as KATHERINE demonstrated the clinical
utility of the neoadjuvant strategy to identify patients with
residual disease who derive a survival benefit from an
escalation in adjuvant therapy, the secondary outcome
results from KRISTINE suggest that patients who achieve
pCR with limited chemotherapy exposure, such as T-
DM11P, have a low recurrence risk. If so, pathologic re-
sponse after neoadjuvant therapy could be used as
a functional biomarker with which to identify patients with
clinical stage II or III disease who might benefit from less
chemotherapy (de-escalation). The challenge then remains
to identify patients who have the highest likelihood of
achieving pCR with less toxic therapy and who will have
excellent long-term outcomes.
Whether on study or in clinical practice, caution is needed
and a careful multidisciplinary approach is mandatory.
Taken together, KRISTINE, KATHERINE, and similar trials
suggest that the neoadjuvant approach in HER2-positive
disease holds the potential to allow for a Goldilocks strategy—
not too much, nor too little therapy—and it is time to le-
verage this further. If all pCRs are created equal, no matter
how achieved, which is what the KRISTINE trial suggests
but has not proven, the goal then should be to achieve pCR
with the least toxic therapy. Unfortunately, all-biologic
regimens, such as HP, in unselected HER2-positive
breast cancers have relatively low pCR rates. Regimens
with limited chemotherapy exposure, such as T-DM11P,
result in a higher pCR frequency; however, T-DM11P also
has a relatively high progression rate during the neo-
adjuvant phase compared with regimens using just a single
free chemotherapy drug, such as NeoSphere,19 Neo-
ALTTO,28 and CALGB 40601.27 Therefore, a careful as-
sessment of HER2 status and possibly additional
biomarkers will be needed to ensure optimal patient se-
lection for neoadjuvant T-DM11P.
Today, patients with HER2-positive breast cancer and
clinical stage I disease should be referred for surgery and
offered adjuvant single-agent paclitaxel and trastuzumab
using the APT regimen if pathologic stage is confirmed. On
the basis of the results from the KATHERINE trial, patients
with clinical stage II and III disease should be offered
preoperative combination chemotherapy plus single or dual
HER2-targeted therapy, and escalation of adjuvant therapy
with T-DM1 for those with residual disease. Finally, al-
though the findings from KRISTINE are promising, it is
premature to endorse pCR for de-escalation in routine
practice, especially when pCR was obtained using HER2-
targeted regimens with limited chemotherapy exposure,
such as T-DM11P. Still, this is clearly a valuable direction
of study, and de-escalation trials guided by pCR and other
markers must now proceed.
In the future, greater individualization in early-stage HER2-
positive disease will be the norm, including the ability to
predict which patients are most likely to achieve pCR with
less therapy. Factors at presentation, such as intrinsic
subtype,27,29 immune activation markers, and HER2 ex-
pression and heterogeneity, as well as factors assessed
after therapy is started, such as functional imaging24 and
cell-free DNA, will further refine the assessment of re-
sponse to therapy by pathologic response categories. The
immediate next steps should be to confirm the implications
from the KRISTINE trial, namely, that survival outcomes
in patients who achieve pCR with HER2-targeted regi-
mens combined with less or no chemotherapy are the
same as those achieved with targeted therapy plus
combination chemotherapy.
AFFILIATIONS
1The Johns Hopkins Kimmel Comprehensive Cancer Center,
Baltimore, MD
2Beth Israel Deaconess Medical Center, Boston, MA
3University of North Carolina Lineberger Comprehensive Cancer Center,
Chapel Hill, NC
CORRESPONDING AUTHOR
Antonio C. Wolff, MD, The Johns Hopkins Kimmel Comprehensive Cancer
Center, 201 N. Broadway, Viragh 10-289, Baltimore, MD 21287; e-mail:
awolff@jhmi.edu.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability statement (if
applicable) are available with this article at DOI https://doi.org/10.1200/
JCO.19.01159.
AUTHOR CONTRIBUTIONS
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
REFERENCES
1. Giuliano AE, Ballman KV, McCall L, et al: Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast
cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318:918-926, 2017
2. Wolff AC, Abeloff MD: Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: It ain’t necessarily so. J Natl Cancer Inst 94:1041-1043,
2002
3. Sparano JA, Gray RJ, Makower DF, et al: Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005-2014, 2015
4. Sparano JA, Gray RJ, Makower DF, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111-121, 2018
5. Thaler RH, Sunstein CR: Nudge. New Haven, CT, Yale University Press, 2008
6. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
7. Perez EA, Romond EH, Suman VJ, et al: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer:
Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744-3752, 2014
8. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al: 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final
analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195-1205, 2017
9. von Minckwitz G, Procter M, de Azambuja E, et al: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122-131,
2017
10. Martin M, Holmes FA, Ejlertsen B, et al: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of
a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18:1688-1700, 2017
11. Tolaney SM, Guo H, Pernas S, et al: Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth
factor receptor 2–positive breast cancer. J Clin Oncol 37:1868-1875, 2019
12. von Minckwitz G, Huang C-S, Mano MS, et al: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617-628, 2019
13. Prowell TM, Beaver JA, Pazdur R: Residual disease after neoadjuvant therapy: Developing drugs for high-risk early breast cancer. N Engl J Med 380:612-615,
2019
14. Morrow M: Management of the node-positive axilla in breast cancer in 2017: Selecting the right option. JAMA Oncol 4:250-251, 2018
15. Cortazar P, Zhang L, UntchM, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:
164-172, 2014
16. Wolff AC, Berry D, Carey LA, et al: Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 26:806-813, 2008
17. Prowell TM, Pazdur R: Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 366:2438-2441, 2012
18. Berry DA, Hudis CA: Neoadjuvant therapy in breast cancer as a basis for drug approval. JAMA Oncol 1:875-876, 2015
19. Gianni L, Pienkowski T, Im Y-H, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
20. Piccart-Gebhart M, Holmes E, Baselga J, et al: Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer:
Results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 34:1034-1042, 2016
21. Rimawi MF, De Angelis C, Contreras A, et al: Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without
chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740, 2018
22. Veeraraghavan J, De Angelis C, Mao R, et al: A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab
without chemotherapy in patients with HER21 breast cancer. Ann Oncol 10.1093/annonc/mdz076 [Epub ahead of print on March 23, 2019]
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